Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study

Table 1 Patient demographics

	EM (n = 15)	IM (n = 7)	p
Age (years)	33.0 (28.0–43.0)	39.0 (29.0–64.0)	0.56^a
Disease duration of schizophrenia (years)	12.0 (6.0–16.5)	9.0 (9.0–40.0)	0.43^a
Gender: female/male	7/8	4/3	0.50^b
Body weight (kg)	63.0 (55.3–78.0)	64.2 (59.2–76.7)	0.96^a
Laboratory data
AST (IU/L)	20 (16–23)	24 (19–32)	0.31^a
ALT (IU/L)	24 (14–33)	22 (17–94)	0.71^a
Albumin (g/dL)	4.5 (4.3–4.7)	4.5 (4.2–4.5)	0.49^a
Bilirubin (mg/dL)	0.60 (0.50–0.90)	0.60 (0.40–0.70)	0.32^a
Serum creatinine (mg/dL)	0.79 (0.69–0.90)	0.74 (0.66–0.84)	0.37^a
eGFR (mL/min/1.73 m²)	79.3 (70.7–91.2)	85.0 (66.7–102.6)	0.64^a
Antipsychotics
Risperidone dose (mg/day)	4.0 (2.0–6.0)	4.0 (2.0–7.0)	0.31^a
Risperidone dose (mg/kg)	0.065 (0.034–0.097)	0.074 (0.053–0.112)	0.55^a
Olanzapine (+/−)	4/11	2/5	0.65^b
Levomepromazine (+/−)	5/10	1/6	0.35^b
Chlorpromazine equivalent dose (mg/day)	500 (400–1010)	475 (250–1800)	0.79^a
Other treatments
Number of concomitant drugs	4 (2–5)	7 (2–8)	0.31^a
Anticholinergics (+/−)	7/8	5/2	0.27^b
Mood stabilizers (+/−)	4/11	3/4	0.39^b
Benzodiazepines (+/−)	12/3	6/1	0.62^b

Data are expressed as the number of patients or median with the interquartile range in parentheses
Two cases (one case in the EM group, the other case in the IM group) were excluded in the body weight and risperidone dose (mg/kg) data, because information on the body weight was not obtained
^aMann–Whitney U test
^bFisher’s exact test
EM extensive metabolizer, IM intermediate metabolizer, AST aspartate aminotransferase, ALT alanine aminotransferase, eGFR estimated glomerular filtration rate

ISSN: 2055-0294